Dr. W. Chan
Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong
Despite the reduction in mortality since the use of corticosteroids, pemphigus vulgaris still carries significant morbidity. This article reviewed recent studies on the use of available adjuvant therapies, including azathioprine, pulse cyclophosphamide, cyclosporine, methotrexate, anti-inflammatory agents, plasmapheresis, mycophenolate mofetil and intravenous immunoglobulins.
Keywords : Adjuvant therapies, pemphigus vulgaris, review
Back to Previous Page